YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection
YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics
YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA-Methylation Blood Test for Post-Treatment Breast Cancer Monitoring
YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES
YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities